Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered to =\< grade 1 adverse events due to agents administered more than 4 weeks earlier

Patients who are receiving any other investigational agents

Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events

History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228) or ziv-aflibercept

Uncontrolled intercurrent illness including active infection

Pregnant women are excluded from this study because MLN0128 (TAK-228) and ziv-aflibercept are agents with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with MLN0128 (TAK-228) and ziv-aflibercept, breastfeeding should be discontinued if the mother is treated with MLN0128 (TAK-228) and ziv-aflibercept; these potential risks may also apply to other agents used in this study

Patients with known human immunodeficiency virus infection are not to be enrolled in the study

History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days or manifestations of malabsorption due to prior gastrointestinal (GI) surgery or GI disease that may alter the absorption of MLN0128 (TAK-228)

New York Heart Association class III or greater congestive heart failure within last 6 months or uncontrolled hyperlipidemia (cholesterol \> 300 mg/dl; triglyceride 2.5 X upper limit of normal \[ULN\] despite lipid lowering agent) within last 3 months

History of uncontrolled hypertension, defined as blood pressure \> 150/95 mmHg, or systolic blood pressure \> 180 mmHg when diastolic blood pressure \< 90 mmHg, on at least 2 repeated determinations on separate days within 3 months prior to study enrollment

Urine protein should be screened by dipstick or urine analysis; for proteinuria \> 1+ or urine protein: creatinine ratio \> 1.0, 24-hour urine protein should be obtained and the level should be \< 2000 mg for patient enrollment

Patients on anticoagulant therapy with unstable dose of warfarin and/or having an out-of- therapeutic range international normalized ratio (INR) (\> 3) within the 4 weeks prior to drug administration

Evidence of clinically significant bleeding diathesis or underlying coagulopathy, non-healing wound

History of any of the following within the last 6 months prior to study entry:

* Ischemic myocardial event, including angina requiring therapy and artery revascularization procedures

* Ischemic cerebrovascular event, including transient ischemic attack (TIA) and artery revascularization procedures

* Requirement for inotropic support (excluding digoxin) or serious (uncontrolled) cardiac arrhythmia (including atrial flutter/fibrillation, ventricular fibrillation or ventricular tachycardia)

* Placement of a pacemaker for control of rhythm

* Pulmonary embolism

Significant active cardiovascular or pulmonary disease at the time of study entry, including:

* Uncontrolled high blood pressure (i.e., systolic blood pressure \> 150 mm Hg, diastolic blood pressure \> 95 mm Hg)

* Pulmonary hypertension

* Uncontrolled asthma or oxygen (O2) saturation \< 90% by pulse oximetry on room air

* Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention, or history of valve replacement

* Medically significant (symptomatic) bradycardia

* History of arrhythmia requiring an implantable cardiac defibrillator

Baseline prolongation of the rate-corrected QT interval (QTc) (e.g. repeated demonstration of QTc interval \> 480 milliseconds, or history of congenital long QT syndrome, or torsades de pointes)

Psychiatric illness/social situations that would limit compliance with study requirements

Have initiated treatment with bisphosphonates less than 30 days prior to the first administration of MLN0128 (TAK-228); concurrent bisphosphonate use is only allowed if the bisphosphonate was initiated at least 30 days prior to the first administration of MLN0128 (TAK-228)

Patients who are taking proton pump inhibitor (PPI) within 7 days before receiving the first dose of study drug or who require treatment with PPIs throughout the trial or those who are taking H2 receptor antagonists within 24 hours of the first dose of study drug

Patients with known history of hepatitis B surface antigen-positive, or known history or suspected active hepatitis C infection are not to be enrolled in the study

What this study is about